Combining Liso-cel with Ibrutinib for Relapsed CLL / SLL
June 24, 2025
Combination liso-cel and ibrutinib produced deep remissions with undetectable MRD in most patients with relapsed / refractory CLL / SLL.
Combination liso-cel and ibrutinib produced deep remissions with undetectable MRD in most patients with relapsed / refractory CLL / SLL.
MRD-guided ibrutinib plus venetoclax is a very effective combination therapy for treating CLL, and it can provide durable responses.
Patients with CLL treated with ibrutinib have a 9-year overall survival rate, irrespective of high-risk features.
Treatment with ibrutinib-venetoclax produced high rates of uMRD and durable progression-free survival in patients with CLL irrespective of lymph node size.
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.
Ibrutinib may be taken alone or in combination with another medication as an initial (first-line) treatment.
Long-term ibrutinib treatment increases T cell numbers and improves T cell function in CLL patients but does not fully restore T cell function.
Long-term follow-up data confirms the sustained benefit of ibrutinib therapy for CLL / SLL, including uMRD, in a small subset of patients.
A combination of ibrutinib plus venetoclax is a very effective first-line treatment for CLL, and 90% of patients are progression-free after five years.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911